Research
Neural
GLP1-RA treatment is not associated with a significant difference in risk of serious psychiatric adverse events compared with placebo (log[RR] = -0.02; P = .87).
GLP1-RAs can be considered safe regarding serious psychiatric events in this population.
StrongRefutesmedium confidence
GLP1-RA treatment was not associated with a significant difference in risk of serious psychiatric adverse events (log[RR] = -0.02; 95% CI, -0.20 to 0.17; P = .87).
Why this rating
Based on a meta-analysis of randomized clinical trials.
Source
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health
Aureliane C. S. Pierret et al. · JAMA Psychiatry · 2025
Meta-analysisCited 61×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →